Fourpath Capital Management
PFE icon

Fourpath Capital Management’s Pfizer PFE Stock Holding History

Fourpath Capital Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.51M Sell
53,088
-1,131
-2% -$30.1K 0.2% 81
2026
Q2 		$1.31M Buy
54,219
+9,504
+21% +$249K 0.17% 100
2026
Q1 		$1.26M Buy
44,715
+5,179
+13% +$138K 0.18% 88
2025
Q4 		$984K Sell
39,536
-6,133
-13% -$155K 0.13% 102
2025
Q3 		$1.16M Buy
45,669
+8,814
+24% +$218K 0.17% 91
2025
Q2 		$893K Buy
36,855
+6,095
+20% +$142K 0.14% 101
2025
Q1 		$779K Buy
30,760
+7,987
+35% +$209K 0.14% 101
2024
Q4 		$604K Sell
22,773
-5,328
-19% -$145K 0.11% 123
2024
Q3 		$813K Buy
28,101
+3,425
+14% +$100K 0.15% 102
2024
Q2 		$690K Sell
24,676
-780
-3% -$21.5K 0.51% 47
2024
Q1 		$706K Buy
25,456
+2,838
+13% +$78.8K 0.49% 49
2023
Q4 		$651K Sell
22,618
-967
-4% -$29.2K 0.44% 47
2023
Q3 		$782K Sell
23,585
-504
-2% -$17.8K 0.59% 36
2023
Q2 		$884K Buy
24,089
+3,162
+15% +$123K 1.06% 27
2023
Q1 		$854K Buy
20,927
+3,933
+23% +$170K 0.6% 35
2022
Q4 		$871K Buy
16,994
+2,218
+15% +$106K 0.63% 39
2022
Q3 		$647K Sell
14,776
-966
-6% -$46.9K 0.44% 53
2022
Q2 		$825K Sell
15,742
-1,619
-9% -$82.5K 0.51% 45
2022
Q1 		$899K Buy
17,361
+4,023
+30% +$209K 0.36% 51
2021
Q4 		$788K Buy
+13,338
New +$661K 0.3% 63

Other funds holding PFE

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Artemis Investment Management
Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
Willis Investment Counsel
Willis Investment Counsel Gainesville, Georgia $1.97B AUM 25.29% 1-Year Est. Return
IFM Investors
IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Fourpath Capital Management's PFE Position: Q3 2026 in Review

Fourpath Capital Management reduced its Pfizer (PFE) stake by 2.1% in Q3 2026, selling an estimated $30.1K and leaving 53,088 shares worth $1.51M. The position accounts for 0.2% of the portfolio, ranked #81.

Fourpath Capital Management first reported a position in PFE in Q4 2021 and has held it in 20 quarters since. 648 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Fourpath Capital Management held 53,088 shares of Pfizer worth $1.51M as of Q3 2026.
  • Fourpath Capital Management sold 1,131 Pfizer shares in Q3 2026, an estimated $30.1K.
  • Pfizer made up 0.2% of Fourpath Capital Management's portfolio in Q3 2026, its #81 holding.
  • Fourpath Capital Management first reported a position in Pfizer in Q4 2021 and has held it in 20 quarters since.
  • 648 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Fourpath Capital Management's 13F filing for Q3 2026, filed 19 Oct 2026.